TrialTrials2022

Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE).

Tania Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.